{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:50:45Z","timestamp":1784991045181,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,22]]},"DOI":"10.7759\/cureus.25218","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T22:50:58Z","timestamp":1653259858000},"source":"Crossref","is-referenced-by-count":8,"title":["Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis"],"prefix":"10.7759","author":[{"given":"Shunya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Shiotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriya","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S125964","article-title":"Dupilumab in the management of moderate-to-severe asthma: the data so far","volume":"13","author":"Barranco P","year":"2017","unstructured":"Barranco P, Phillips-Angles E, Dominguez-Ortega J, Quirce S. Dupilumab in the management of moderate-to-severe asthma: the data so far. Ther Clin Risk Manag. 2017, 13:1139-49. 10.2147\/TCRM.S125964","journal-title":"Ther Clin Risk Manag"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert C","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, et al.. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019, 394:1638-50. 10.1016\/s0140-6736(19)31881-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123890","article-title":"Role of cytokines in EGPA and the possibility of treatment with an anti-IL-5 antibody","volume":"9","author":"Isozaki T","year":"2020","unstructured":"Isozaki T, Homma T, Sagara H, Kasama T. Role of cytokines in EGPA and the possibility of treatment with an anti-IL-5 antibody. J Clin Med. 2020, 9:3890. 10.3390\/jcm9123890","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe KF","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, et al.. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018, 378:2475-85. 10.1056\/NEJMoa1804093","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro M","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al.. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018, 378:2486-96. 10.1056\/NEJMoa1804092","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805283382206","article-title":"Eosinophilia","volume":"338","author":"Rothenberg ME","year":"1998","unstructured":"Rothenberg ME. Eosinophilia. N Engl J Med. 1998, 338:1592-600. 10.1056\/NEJM199805283382206","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13514","article-title":"Blockade of IL-4R\u03b1 inhibits group 2 innate lymphoid cell responses in asthma patients","volume":"50","author":"Patel G","year":"2020","unstructured":"Patel G, Pan J, Ye L, et al.. Blockade of IL-4R\u03b1 inhibits group 2 innate lymphoid cell responses in asthma patients. Clin Exp Allergy. 2020, 50:267-70. 10.1111\/cea.13514","journal-title":"Clin Exp Allergy"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts R","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, et al.. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007, 66:222-7. 10.1136\/ard.2006.054593","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.02.042","article-title":"Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma","volume":"9","author":"Eger K","year":"2021","unstructured":"Eger K, Pet L, Weersink EJ, Bel EH. Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract. 2021, 9:2913-5. 10.1016\/j.jaip.2021.02.042","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1697678","article-title":"Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease","volume":"16","author":"Berti A","year":"2020","unstructured":"Berti A, Boukhlal S, Groh M, Cornec D. Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease. Expert Rev Clin Immunol. 2020, 16:51-61. 10.1080\/1744666X.2019.1697678","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/96174-exacerbation-of-eosinophilic-granulomatosis-with-polyangiitis-after-administering-dupilumab-for-severe-asthma-and-eosinophilic-rhinosinusitis-with-nasal-polyposis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:42:16Z","timestamp":1707507736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/96174-exacerbation-of-eosinophilic-granulomatosis-with-polyangiitis-after-administering-dupilumab-for-severe-asthma-and-eosinophilic-rhinosinusitis-with-nasal-polyposis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,22]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.25218","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,22]]}}}